- Home
- ASG vs PRQR Comparison
ASG vs PRQR Comparison
Compare ASG & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- PRQR
- Stock Information
- Founded
- ASG 1986
- PRQR 2012
- Country
- ASG United States
- PRQR Netherlands
- Employees
- ASG N/A
- PRQR N/A
- Industry
- ASG Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ASG Finance
- PRQR Health Care
- Exchange
- ASG Nasdaq
- PRQR Nasdaq
- Market Cap
- ASG 327.8M
- PRQR 179.1M
- IPO Year
- ASG N/A
- PRQR 2014
- Fundamental
- Price
- ASG $5.52
- PRQR $2.45
- Analyst Decision
- ASG
- PRQR Strong Buy
- Analyst Count
- ASG 0
- PRQR 8
- Target Price
- ASG N/A
- PRQR $8.88
- AVG Volume (30 Days)
- ASG 324.3K
- PRQR 365.1K
- Earning Date
- ASG 01-01-0001
- PRQR 08-07-2025
- Dividend Yield
- ASG 8.09%
- PRQR N/A
- EPS Growth
- ASG N/A
- PRQR N/A
- EPS
- ASG N/A
- PRQR N/A
- Revenue
- ASG N/A
- PRQR $21,212,711.00
- Revenue This Year
- ASG N/A
- PRQR N/A
- Revenue Next Year
- ASG N/A
- PRQR N/A
- P/E Ratio
- ASG N/A
- PRQR N/A
- Revenue Growth
- ASG N/A
- PRQR 85.91
- 52 Week Low
- ASG $4.47
- PRQR $1.07
- 52 Week High
- ASG $5.71
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ASG 66.99
- PRQR 71.45
- Support Level
- ASG $5.42
- PRQR $2.10
- Resistance Level
- ASG $5.54
- PRQR $2.42
- Average True Range (ATR)
- ASG 0.07
- PRQR 0.14
- MACD
- ASG 0.01
- PRQR 0.02
- Stochastic Oscillator
- ASG 99.71
- PRQR 73.17
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.